Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men

I. Mary Poynten⁎, Sepehr N. Tabrizi, Fengyi Jin, David J. Templeton, Dorothy A. Machaley, Alyssa Corrain, Samuel Phillips, Christopher K. Fairley, Suzanne M. Garland, Carmella Law, Andrew Catt, Richard J. Hillman, Andrew E. Grulich, SPANC Study Team

A. The Kirby Institute, University of New South Wales, Sydney, Australia
B. Regional HPV LabNet Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Parkville, Victoria, Australia
C. Department of Obstetrics and Gynecology, University of Melbourne, Victoria, Australia
D. Murdoch Children’s Research Institute, Parkville, Victoria, Australia
E. RPA Sexual Health and Central Clinical School, University of Sydney, Sydney, Australia
F. Melbourne Sexual Health Centre, Alfred Health, Carlton, Melbourne, Victoria, Australia
G. Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia
H. Department of Microbiology and Infectious Diseases, Royal Women’s Hospital, Parkville, Melbourne, Victoria, Australia
I. St Vincent’s Hospital, Sydney, Australia
J. Western Sydney Sexual Health Centre, University of Sydney, Sydney, Australia

ARTICLE INFO

Keywords:
Human papillomavirus
HPV
Anal
Vaccine
Prevalence
Gay and bisexual men
 MSM
HIV

Abstract

Objective: HPV causes ~90% of anal cancer and HPV16 is the type most commonly associated with anal cancer. Gay and bisexual men (GBM) are at greatly increased risk. We investigated patterns of vaccine-preventable anal HPV in older GBM.

Methods: The Study of the Prevention of Anal Cancer (SPANC) is an ongoing, prospective cohort study of HIV-positive and HIV-negative Australian GBM. Participants completed questionnaires and underwent an anal swab for HPV genotyping using Roche Linear Array. We analysed baseline data from SPANC by HPV type, mean number of types, stratified by age and HIV status.

Results: Anal HPV results from 606 (98.2%) of 617 participants (median age 49 years, 35.7% HIV-positive) showed 525 (86.7%) had ≥1 HPV type and 178 (29.4%) had HPV16. Over one third of participants (214, 35.3%) had no nonavalent vaccine-preventable types detected. Two (0.3%) participants had all quadrivalent types and none had all nonavalent vaccine types. HIV-positive participants (p < 0.001) and younger participants (p=0.059) were more likely to have more vaccine-preventable HPV types detected.

Conclusion: Anal HPV was highly prevalent in this largely community-based GBM cohort. Vaccine-preventable HPV16 was detected in approximately one third of participants. These findings suggest that the potential efficacy of HPV vaccination of older GBM should be explored.

1. Introduction

Squamous cell carcinoma of the anal canal (“anal cancer”) is rare, but its incidence has been increasing worldwide for decades [1–4]. A key feature of anal cancer epidemiology is that its occurrence is heavily concentrated in certain population subgroups. Anal cancer is caused by anal exposure to human papillomavirus (HPV) and for this reason gay and bisexual men (GBM) are at particularly high risk, experiencing rates of anal cancer that are at least 20-fold higher than the general population [5]. The overall rates of anal cancer in people living with HIV are 30-fold higher than in the general population [6], but HIV positive GBM are the most affected population due to their combination of impaired immune function and increased anal HPV exposure, with up to a 100-fold higher incidence of anal cancer reported [7].

Anal cancer is believed to be preceded by persistent infection with high-risk types of HPV (HrHPV), with HPV16 comprising a large

⁎ Corresponding author.
E-mail address: mpoynten@kirby.unsw.edu.au (I.M. Poynten).

http://dx.doi.org/10.1016/j.pvr.2017.02.003
Received 22 September 2016; Received in revised form 16 January 2017; Accepted 16 February 2017
Available online 21 February 2017
2405-8521/ Crown Copyright © 2017 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
majority (75–80%) [8]. The strong association between anal HPV infection and cancer indicates that anal cancer is potentially preventable by HPV vaccination [9], with either the quadrivalent HPV vaccine (4vHPV) or the nonavalent HPV vaccine (9vHPV). There is evidence of HPV vaccine efficacy in prevention of cervical infection and disease in sexually active women aged up to 45 years [10–12] and in anal infection and disease in GBM aged up to 26 years [13]. Despite HPV-related anal cancer being one of the most pressing health issues in GBM, very few data exist to inform the potential efficacy of HPV vaccination in those aged older than 26 ("older GBM"). There is a concern that many older GBM may be currently HPV infected, and there is evidence that the vaccine does have an impact on current infections [14]. We explored patterns of vaccine-preventable anal HPV in a community-based cohort of older HIV-positive and HIV-negative Australian GBM.

2. Methods

2.1. Study design

The Study of Prevention of Anal Cancer (SPANC) is a prospective cohort study of the epidemiology of anal HPV infection and related cytological and histological anal abnormalities in GBM aged 35 years and older in Sydney, Australia. The methods of the study have been described in detail elsewhere [15]. Briefly, men aged ≥35 years who reported having sex with another man in their lifetime were eligible. Participants were recruited mainly from community-based settings in Sydney, including gay community social events and organizations, as well as referrals from other participants. At the baseline visit, participants completed a detailed risk factor questionnaire and had an anal swab for cytology and HPV DNA testing.

Signed, informed consent was provided by all participants. Ethics approval was granted by the Human Research Ethics Committees of St. Vincent’s Hospital, Sydney, the Royal Prince Alfred Hospital, Sydney and the University of New South Wales.

2.2. Anal HPV genotyping

The PreservCyt anal swab specimens were tested for HPV DNA using the Roche Linear Array (LA) HPV genotyping test (Roche Molecular Systems, Alameda, CA, United States). DNA was extracted with the automated MagNA Pure isolation and purification system (Roche) by a modified protocol using 1 ml aliquots of PreservCyt specimens as described previously [16]. The LA HPV genotyping test involves PCR amplification of a 450 bp region of the HPV L1 gene and allows for the identification of 37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 (HPV 82v subtype), and CP6108 (HPV 89) as well as amplification of a 265 bp region of the human ß-globin gene, serving as an internal control. As an in-house modification, samples that produced a negative internal control were retested with half the volume of eluted DNA, in order to reduce inhibition due to bacterial DNA in those samples. In addition, due to possible cross-reactivity of the HPV-52 probe with types 33, 35, and 58 amplicons, samples positive for one or more of HPV-33, 35, and 58 probes were further tested using a real-time PCR assay with an HPV52 specific hydrolysis probe to confirm the presence or absence of HPV52 in addition to those types [17].

2.3. Statistical analyses

The exact binomial method was used to calculate 95% confidence intervals (CIs) for anal HPV prevalence values for each HPV type and vaccine-targeted HPV types, (4vHPV: HPV6, HPV11, HPV16 and HPV18 and 9vHPV: HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52 and HPV58). Generalised linear regression was used for univariate analyses to identify the association of number of vaccine-preventable anal HPV types with age and/or HIV status. A t-test was used to test for trend for means. A rank sum test was then performed as a sensitivity analysis, to test the robustness of the results. Among HIV-positive men, nadir and current CD4+ T-cell counts were also assessed. STATA Version 14 (StataCorp, College Station, Texas USA) was used for the analysis.

3. Results

A total of 617 men were enrolled in SPANC, with a median age of 49 years (range 35–79 years). Nearly all men (588, 95.3%) identified as gay or homosexual. Greater than one-third (220, 35.7%) were HIV-positive (Table 1). The great majority of these men (206, 93.6%) were currently receiving antiretroviral therapy, reported an undetectable viral load (197, 89.5%) and had a CD4 T-cell count of more than 350 cells/μL (194, 88.0%). Of the 582 men (94.3%) who completed a

| Table 1 | SPANC participant baseline characteristics by HIV status (n=617). |
|---------|---------------------------------------------------------------|
|         | Overall | HIV negative n=397 | HIV positive n=220 |
| Age (year groups) |         |                   |                   |
| 35–44   | 198     | 134               | 64               |
| 45–54   | 236     | 141               | 95               |
| 55–64   | 124     | 76                | 48               |
| ≥65     | 59      | 46                | 13               |
| Cigarette smoking status |         |                   |                   |
| Never   | 334     | 232               | 102              |
| Past smoker | 196     | 121               | 75               |
| Current smoker | 87      | 44                | 43               |
| Sexual identity |         |                   |                   |
| Heterosexual or straight |    4    | 3                 | 1                |
| Bisexual | 17      | 11                | 6                |
| Gay     | 390     | 256               | 134              |
| Queer   | 8       | 4                 | 4                |
| Homosexual | 190     | 120               | 70               |
| Other   | 8       | 3                 | 5                |
| Lifetime number of male sexual partners |         |                   |                   |
| < 10    | 11      | 10                | 1                |
| 11–50   | 102     | 81                | 21               |
| 51–200  | 173     | 116               | 57               |
| 201–500 | 122     | 76                | 46               |
| > 500   | 196     | 105               | 91               |
| Lifetime number of R-CLAI partners |         |                   |                   |
| 0–1     | 84      | 74                | 10               |
| 2–5     | 165     | 146               | 19               |
| 6–10    | 125     | 84                | 41               |
| > 10    | 243     | 93                | 150              |
| Number of male sexual partners in past 6 months |         |                   |                   |
| None    | 49      | 15                | 34               |
| 1       | 123     | 90                | 33               |
| 2–5     | 164     | 114               | 50               |
| 6–10    | 106     | 65                | 41               |
| > 10    | 175     | 113               | 62               |
| Number of R-CLAI partners in past 6 months |         |                   |                   |
| None    | 289     | 194               | 95               |
| 1       | 184     | 142               | 42               |
| ≥2      | 144     | 61                | 83               |

* R-CLAI – participant reports receptive anal intercourse without a condom.
baseline question on HPV vaccination status, very few (15, 2.6%) reported receiving any prior vaccination.

3.1. Prevalent anal HPV detection

Six-hundred and six (98.2%) participants had baseline anal HPV results available. Testing was inhibited on the remaining 11 (1.8%) participants and they were excluded from further analysis. Of the 606 men with an adequate samples, 525 (86.6%) had at least one anal HPV type detected. A single HPV type was detected in 101 participants (16.7%), while the rest had multiple HPV types detected. Nineteen participants (3.1%) had more than 10 HPV types detected. The prevalence of any anal HPV was 94.5% (207) in HIV-positive men and 82.2% (318) in HIV-negative men (p < 0.001).

Only two participants (0.3%, both aged between 35 and 44 years) were positive for all 4vHPV types. No participant was positive for all 9vHPV types. Almost half the participants had no 4vHPV types detected (298, 49.2%) and this ranged from 42.1% (82) of men aged 35–44 years to 66.1% (39) of men aged 65 years or more. More than a third of participants had no 9vHPV vaccine types detected (214, 35.3%), ranging from 32.8% (64) of men aged 35–44 years to 50.8% (30) of men aged 65 years or more. Of the vaccine-preventable types, HPV16 was by far the most prevalent type, with a prevalence of 29.4% (178 participants), followed by HPV6 (18.0%, 109 participants) and HPV45 (13.9%, 84 participants) (Table 2).

3.2. Predictors of prevalent anal vaccine-preventable HPV types

Of the 9vHPV types, HPV31 (p=0.012), HPV52 (p < 0.001) and HPV58 (p < 0.001) were significantly more prevalent in HIV-positive than HIV-negative participants. There was no difference in HPV16 prevalence by HIV status (p=0.29) (Fig. 1). Overall, prevalence was lower for all vaccine-preventable HPV types among men aged 65 and above. Prevalence of HPV18 (p=0.001), and the genital and anal wart-associated low risk HPV types, HPV6 (p=0.004) and HPV11 (p=0.002) declined across the four age groups (Table 2). Prevalence of the other types did not vary with age, however, the prevalence of HPV16 in men aged 65 years and older was significantly lower than in men younger than 65 years (p=0.042).

Among men with anal HPV, the mean number of 9vHPV types was significantly higher among HIV positive participants (1.69 in the HIV negative and 2.05 in the HIV positive, p < 0.001) and higher among younger men (p trend=0.059) (Table 3). Younger men compared with older men and HIV-positive men compared with HIV-negative men, were more likely to have at least one vaccine-preventable HPV type detected, (p=0.003 and p < 0.001 respectively) (Table 2). Among HIV positive men, lower current CD4 T cell count was associated with detection of at least one vaccine preventable HPV type (p=0.008 for 4vHPV and p=0.003 for 9vHPV for CD4 count ≤350 cells/μL versus higher). Similarly, lower nadir CD4 T cell count was associated with detection of at least one vaccine preventable HPV type (p=0.013 for 4vHPV and p < 0.001 for 9vHPV).

4. Discussion

The vast majority of this largely community-based GBM cohort had prevalent anal HPV (525 men, 86.6%). HPV16, the type which is most commonly associated with anal cancer and which is targeted by the 4vHPV and 9vHPV vaccines, was detected in nearly 30% (178 participants). More than one third had no 9vHPV types detected. Men younger than 45 years and HIV positive men were more likely to have at least one vaccine-preventable HPV type and to have higher mean numbers of 9vHPV types detected. Only two participants had all 4vHPV vaccine-related types detected and none had all 9vHPV vaccine-related types detected. A number of cross-sectional and prospective cohort studies around the world have measured anal HPV prevalence in GBM [18–27]. Most report a similar prevalence of any anal HPV infection to that found in this cohort, although prevalence varies depending on the proportion of men who are HIV-positive. HIV-positive men generally have a higher prevalence of anal HPV [20,26]. Similar rates of HPV16 detection have been reported in all studies discussed above, with prevalence between 27% and 35% [18–21,24]. However a cohort study of HIV-negative GBM in Brazil, Mexico and the USA found much lower prevalence of HPV16 of 6.3%, despite 63.5% of participants reporting a recent male anal sex partner [25]. These differences in anal HPV prevalence are likely to be at least partly explained by differences in HPV genotyping assays [18–22,25,27] or to demographic or behavioural differences in the study populations.

Although heterosexual men appear to benefit from substantial herd protection from HPV-related disease in settings with high rates of female vaccination, gay and bisexual men do not benefit from such herd protection [28]. In our study, only two participants were positive for all 4vHPV vaccine types and none was positive for all 9vHPV vaccine types. Less than one-third had HPV16, the type most likely to cause anal cancer. Almost half the participants had no 4vHPV vaccine types detected and more than one third of participants had no 9vHPV vaccine types detected. However, in serological studies of Australian GBM, older age was significantly associated with HPV16 seropositivity, indicating previous HPV16 infection [29]. Given the high exposure reported by SPANC participants, many anal HPV infections would have

Table 2

| 9v HPV type | Overall prevalence (n=606) | Age (years) | P trend |
|-------------|---------------------------|------------|---------|
|             | % (n)                     | 35–44 (n)  | 45–54 (n) | 55–64 (n) | 65+ (n) |  
| HPV16       | 29.4 (178)                | 28.2 (55)  | 30.6 (70) | 33.3 (41) | 20.3 (12) | 0.74 |
| HPV18       | 12.2 (74)                 | 18.5 (36)  | 10.9 (25) | 8.1 (10)  | 5.1 (3)   | 0.001|
| HPV31       | 5.9 (36)                  | 5.1 (10)   | 7.0 (16)  | 4.9 (6)   | 6.8 (4)   | 0.82 |
| HPV33       | 5.1 (31)                  | 5.1 (10)   | 6.1 (14)  | 4.9 (6)   | 1.7 (1)   | 0.40 |
| HPV45       | 13.9 (84)                 | 15.9 (31)  | 14.0 (32) | 11.4 (14) | 11.9 (7)  | 0.25 |
| HPV52       | 13.5 (82)                 | 15.4 (30)  | 13.5 (31) | 12.2 (15) | 10.2 (6)  | 0.25 |
| HPV39       | 11.1 (67)                 | 11.3 (22)  | 10.5 (24) | 12.2 (15) | 10.2 (6)  | 0.99 |
| HPV6        | 18.0 (109)                | 22.1 (43)  | 17.9 (41) | 13.8 (17) | 13.6 (8)  | 0.04 |
| HPV11       | 9.6 (58)                  | 13.3 (26)  | 8.7 (20)  | 8.1 (10)  | 3.4 (2)   | 0.02 |

![Fig. 1. Prevalence of vaccine-preventable anal HPV types by HIV status in gay and bisexual men.](image)
already cleared naturally, indicating that if they were reinfected they would be likely to clear the infection again. These findings, combined with the concentration of HPV-related cancers among GBM and the fact that very few data exist to inform the potential efficacy of HPV vaccination in older GBM, provide support for the need for randomized trials of HPV vaccination in older GBM.

A strength of the SPANC study is that recruitment was primarily through community sources; thus the study population is likely to be representative of the broader GBM community in Sydney. Both HIV-positive and HIV-negative men were enrolled, enabling us to determine difference in prevalence by HIV status. Apart from the clinic-based study by Schwartz et al., of 305 HIV-positive MSM in San Francisco [22], all other study populations discussed here had a median age of less than 44 years [21, 23–27]. Our older study population allows us to present data in decade strata in ages up to 65 years, and in a substantial number of even older men. This provides an important insight into anal HPV prevalence at the ages where the risk of anal cancer increases.

A potential limitation of the presented analysis is that HPV prevalence is measured at a single time point, and thus persistence is not assessed, meaning that many of these detections may represent short term acute infections rather than the chronic infection which is likely to precede cancer development. The prospective design of the SPANC study will allow us to address this in coming years, as testing at multiple endpoints will determine persistence and reinfection or reactivation. The Linear Array HPV genotyping may favour the multiple endpoints will determine persistence and reinfection or reactivation. The Linear Array HPV genotyping may favour the

Table 3
Number of 9v HPV types detected, overall and by HIV status and age (n=606).

| No of 9v vaccine HPV types | Prevalence | Prevalence by HIV status | Prevalence by age |
|----------------------------|------------|-------------------------|-------------------|
|                            | % (n)      | Negative % (n)          | Positive % (n)    | P value |
|                            |            | n<186                   | n>220             |         |
| 0                          | 35.3 (214) | 32.6 (126)              | 27.7 (61)         | < 0.001 |
| 1                          | 46.4 (182) | 32.4 (125)              | 25.9 (57)         | 32.8 (64) |
| 2                          | 32.9 (129) | 18.4 (71)               | 26.4 (58)         | 28.7 (56) |
| 3                          | 14.0 (55)  | 7.0 (27)                | 12.7 (28)         | 20.5 (40) |
| 4                          | 4.3 (17)   | 1.6 (6)                 | 5.0 (11)          | 3.6 (7)  |
| 5                          | 2.0 (8)    | 0.78 (3)                | 2.3 (5)           | 3.1 (6)  |
| 6                          | 0.26 (1)   | 0.26 (1)                | 0                 | 0.51 (1) |
| 7                          | 0          | 0                       | 0                 | 0       |
| 8                          | 0          | 0                       | 0                 | 0       |
| 9                          | 0          | 0                       | 0                 | 0       |
| Mean typesa                | 1.69       | 2.05                    | < 0.001b          |

a Among those men with at least one HPV type detected.

b A t-test was used to obtain p values.

The Linear Array HPV genotyping may favour the multiple endpoints will determine persistence and reinfection or reactivation. The Linear Array HPV genotyping may favour the

Conflict of interest

Professor Andrew Grulich has received honoraria and research funding from CSL Biotherapies, honoraria and travel funding from MSD. Professor Christopher Fairley has received honoraria, travel funding and research funding from CSL and MSD, and owns shares in CSL Biotherapies. Professor Suzanne Garland has received advisory board fees and grant support from CSL and GlaxoSmithKline, and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, has received funding through her institution to conduct HPV vaccine studies for MSD and GSK and is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. Associate Professor Richard J Hillman has received support from CSL Biotherapies and MSD. Professor Andrew Carr has received research funding from Bristol-Myers Squibb, Gilead Sciences, MSD, and ViV Healthcare; consultancy fees from Gilead Sciences, Mayne Pharma, MSD, and ViV Healthcare; lecture and travel sponsorships from Bristol-Myers Squibb, Gilead Sciences, MSD, and ViV Healthcare; and has served on advisory boards for Gilead Sciences, MSD, and ViV Healthcare. All other authors have no conflicts of interest to declare.

Acknowledgements

We would like to acknowledge and thank the participants of the SPANC study. The SPANC study team includes Brian Acraman, Marjorie Adams, Claire Biro, Andrew Carr, Susan Carroll, David Cooper, Alyssa Cornall, Leonie Crampton, Deborah Ekman, Christopher Fairley, Annabelle Farnsworth, Lance Feeney, Eddie Fraissard, Marko Garcia, Suzanne Garland, Andrew Grulich, Richard Hillman, Kirsten Howard, Fengyi Jin, Johann Kolstee, Carmella Law, Matthew Law, Dorothy Machalek, Kirsten McCaffrey, Ross McDonald, Patrick McGrath, Robert Mellor, Susan Pendlebury, Kathy Petounenos, Piero Pezzopane, Samuel Phillips, Mary Poynten, Garrett Prestage, Adele Richards, Jennifer Roberts, Daniel Seeds, Sepehr Tabrizi, David Templeton, Julia Thurloe, Winnie Tong and Rick Varma.

Funding

This work was supported by the National Health and Medical Research Council Program Grant (Sexually transmitted infections: Causes, consequences and interventions Grant #568971); and a Cancer Council New South Wales Strategic Research Partnership Grant (Preventing morbidity and mortality from anal cancer Grant #13–11). Cytological testing materials were provided by Hologic (Australia) Pty Ltd. The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales and funded by the Australian Government of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government.

References

[1] D. Robinson, V. Coupland, H. Möller, An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast...
England, Br. J. Cancer 100 (2009) 527–531.
[2] D. Forman, C. de Martel, C., I.S. Lacey, J. Lortet-Tieulent, L. Bruni, et al., Global burden of human papillomavirus and related diseases, Vaccine 30 (Suppl 5) (2012) S912–S923.
[3] L. Johnson, M. Madeleine, L. Schwartz, J. Daling, Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000, Cancer 101 (2004) 281–288.
[4] P. Jin, A. Stein, E. Conway, D. Regan, M. Law, J. Brotherton, et al., Trends in anal cancer in Australia, 1982–2005. Vaccine 29 (2011) 2322–2327.
[5] J. Daling, N. Weiss, T. Hilsop, C. Maden, R. Coates, K. Sherman, et al., Sexual practices, sexually transmitted diseases, and the incidence of anal cancer, N. Engl. J. Med. 317 (1987) 973–977.
[6] A. Grulich, M. van Leeuwen, M. Falster, C. Vajdic, Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis, Lancet 370 (2007) 59–67.
[7] D. Machalek, I. Poynten, F. Jin, C. Fairley, A. Farnsworth, S. Garland, et al., Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis, Lancet Oncol. 13 (2012) 487–500.
[8] H. De Vuyst, G. Cliftord, M. Nascimento, M. Madeleine, S. Franceschi, Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis, Int. J. Cancer 124 (2009) 1628–1636.
[9] J. Daling, M. Madeleine, L. Johnson, K. Shera, M. Wurscher, J. Carter, et al., Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer, Cancer 101 (2004) 270–280.
[10] K. Castellsagué, N. Muñoz, P. Pitschmann, T. Ferri, J. Monsonego, K. Ault, et al., End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age, Br. J. Cancer 105 (2011) 28–37.
[11] S. Skinner, A. Szarewski, B. Romanowski, S. Garland, E. Lazzaro-Ponce, J. Salmerón, et al., Efficacy, safety, and immunogenicity of the HPV 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study, Lancet 384 (2014) 2213–2227.
[12] C. Wheeler, S. Skinner, M. Del Rosario-Raymundo, S. Garland, A. Chatterjee, E. Lazzaro-Ponce, et al., Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect. Dis. (2016). http://dx.doi.org/10.1016/S1473-3099(16)30120-7.
[13] A. Giuliano, J. Palefsky, S. Goldstone, E.J. Moreira, M. Penny, C. Aranda, et al., Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males, N. Engl. J. Med. 364 (2011) 401–411.
[14] A. Hildesheim, R. Herrero, S. Wacholder, A. Rodriguez, D. Solomon, M. Bratti, et al., Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial, J. Am. Med. Assoc. 298 (2007) 743–753.
[15] D. Machalek, A. Grulich, R. Hillman, F. Jin, D. Templeton, S. Tabrizi, et al., The Study of the Prevention of Anal Cancer (SPANC): design and methods of a three-year prospective cohort study, BMC Public Health (2013) 13. http://dx.doi.org/10.1186/1471-2458-13-946.
[16] S. Tabrizi, M. Stevens, S. Chen, E. Rudland, J. Kornegay, S. Garland, Evaluation of a modified reverse line blot assay for detection and typing of human papilloma-virus, Am. J. Clin. Pathol. 125 (2006) 896–899.
[17] M. Stevens, S. Garland, S. Tabrizi, Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche Light Cycler 480 system, J. Virol. Methods 147 (2008) 290–296.
[18] S. Videla, L. Darwich, M. Canadas, J. Coll, M. Pinol, F. García-Cuyas, et al., Natural history of Human Papillomavirus Infections involving anal, penile, and oral sites among HIV-positive men, Sex. Transm. Dis. 40 (2013) 3–10.
[19] C. Sadler, D. Rowley, D. Morley, S. Surah, S. D’Oea, S. Delamere, et al., Prevalence of human papillomavirus in men who have sex with men in the era of an effective vaccine; a call to act, HIV Med. 15 (2014) 499–504.
[20] A. Schofeld, L. Sadler, L. Nelson, M. Gittins, M. Desai, A. Sargent, et al., A prospective study of anal cancer screening in HIV positive and negative men who have sex with men; results of analogy, AIDS (2016).
[21] N. Nagata, K. Watanabe, T. Nishijima, K. Tadokoro, K. Watanabe, T. Shimbo, et al., Prevalence of anal Human Papillomavirus Infection and risk factors among HIV-positive patients in Tokyo, Japan. PLoS One 10 (2015) e0137434.
[22] L. Schwartz, P. Castle, S. Follansbee, S. Boronovo, B. Fetterman, D. Tokugawa, et al., Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men. J. Infect. Dis. 208 (2013) 1768–1775.
[23] M. Donà, G. Palamara, A. Di Carlo, A. Latini, A. Vocature, M. Benevolo, et al., Prevalence, genotype diversity and determinants of anal HPV infection in HIV-uninfected men having sex with men, J. Clin. Virol. 54 (2012) 185–189.
[24] M. Torres, C. González, J. del Romero, P. Viciana, O. Amparo, F. Rodríguez-Fortuzé, et al., Anal human papillomavirus genotype distribution in HIV-infected men who have sex with men by geographical origin, age, and cytological status in a Spanish cohort, J. Clin. Microbiol. 51 (2013) 3512–3520.
[25] A. Niyitrar, R. Carvalho da Silva, M. Baggio, B. Lu, D. Smith, M. Abrahamzien, et al., Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J. Infect. Dis. 203 (2011) 49–57.
[26] Y. Hu, H. Qian, J. Sun, L. Gao, L. Yin, X. Li, et al., Anal human papillomavirus infection among HIV-infected and uninfected men who have sex with men in Beijing, China. J. Acquir. Immune Defic. Syndr. 64 (2013) 103–114.
[27] F. van Aar, S. Mouj, M. van der Sande, A. Speksnijder, I. Stolte, C. Meijer, et al., Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM, AIDS 27 (2013) 2921–2931.
[28] B. Donovan, N. Franklin, R. Guy, A. Grulich, D. Regan, H. Ali, et al., Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data, Lancet Infect. Dis. 11 (2011) 39–44.
[29] I. Poynten, F. Jin, D. Templeton, G. Prestage, B. Donovan, M. Pawlita, et al., Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men, J. Infect. Dis. 208 (2013) 1768–1775.
[30] A. Cornall, S. Phillips, E. Cummins, S. Garland, S. Tabrizi, In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: implications for post-vaccination surveillance studies, J. Virol. Methods 214 (2015) 10–14.
